Sudarshan Pharma: New Strategic Development Plans Attracts Warrant Issues, Purchases And Growth Plans

On Tuesday, shares of Pharma company Sudarshan Pharma Industries Ltd surged around 4.25 per cent to an intraday high of Rs 45.20 per share from its previous closing of Rs 43.39 per share. The stock's 52-week high is Rs 46 and its 52-week low is Rs 5.82. The company has a market cap of over Rs 1,090 crore with multibagger returns of over 622 per cent in 5 years.

The Board approved the allotment of 9,00,000 convertible warrants to promoters Mr Hemal V. Mehta and Mr Sachin V. Mehta. Each Warrant which is priced at Rs 169.83 is convertible into 10 equity shares of Rs 1 each with the latter being the new par value after equity share sub-division from Rs 10 per share. The aggregate nominal value of the issue is Rs 15.28 crores of which 25% of the amount is received before acceptance. After the adjustment, these warrants will now be converted to issued 90,00,000 equity shares of Re 1 each.

The stock split, starting on November 22, 2023, resulted in the reduction of the equity value of the company shares from Rs 10 to Re 1 each which improved the liquidity of the shareholders.

SPIL intends to expand its reach in the world market by buying 100% equity in Sudarshan Pharma Industries Private Limited, a wholesale trading company based in Singapore dealing in industrial chemicals. The deal, which cost Singapore $10,000, reveals the company's intentions on wanting to do business in Singapore and its surrounding countries. The Transaction if not categorized as a related party transaction is a cash-only purchase where there approval of the regulatory bodies is minimal.

In a different move, SPIL has increased its stake in Ishwari Healthcare Private Limited to over 51% thus making it a subsidiary of SPIL. Ishwari Healthcare is vertically integrated and operates in the healthcare value chain which includes manufacturing and distribution of medical and surgical instruments, equipment, and devices. This acquisition is in accordance with the management's dictated strategy of SPIL to enter diversification and expansion in the healthcare industry.

SPIL was founded in Mumbai in 2008, and its core competency is contract manufacturing of specialty chemicals, intermediates and APIs, and pharmaceutical generics as well as bulk supply and targeting numerous segments. Its Vimac Healthcare division does the marketing of the branded products, out of the 96 items registered under the "R" brand, 56 items are registered.

Indian contract manufacturing turnkey solution provider SPIL is associated with leading Indian companies and institutional clients.

These initiatives are also an affirmation of the Sudarshan Pharma Industries Ltd senior management's resolve to foster growth and scale up business presence and value for various stakeholders. The organization has been able to further entrench itself as a business leader in the pharmaceutical and healthcare sectors.